PartnershipJun 10, 2026, 09:05 AM
Vivos Therapeutics Forms AIM Florida LLC with SPCVA for OSA Treatment
AI Summary
Vivos Therapeutics, Inc. announced a collaboration agreement with South Palm Cardiovascular Associates (SPCVA) to establish AIM Florida, LLC. This new management services organization aims to expand access to integrated diagnostic and therapeutic clinical treatment services for cardiovascular disease patients in Florida who also suffer from obstructive sleep apnea (OSA) and insomnia. Vivos expects to hold at least 80% of AIM Florida, with SPCVA holding up to 20%. The company projects the model to contribute to cash flow and profitability, with an initial Sleep Optimization Team generating over $6 million annually with contribution margins approaching 50%.
Key Highlights
- Vivos Therapeutics collaborates with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC.
- AIM Florida will expand access to integrated diagnostic and therapeutic services for CVD patients with OSA and insomnia.
- Vivos expects to hold not less than 80% of AIM Florida's membership interests.
- SPCVA will hold up to 20% of AIM Florida's membership interests.
- Initial operations will focus on the Palm Beach County, Florida market.
- One Sleep Optimization Team is projected to serve 250 patients per month.
- This team is expected to generate over $6,000,000 per year.
- Contribution margins are projected to approach 50% once fully deployed.
Price Impact
More from VVOS